MIRM enters its May 6 Q1 earnings report with a substantial short position and a stock that just broke sharply higher — a combination that makes Thursday's release genuinely consequential for both sides of the trade.
Short sellers are carrying a meaningful load into the print. Short interest has climbed to 15.6% of the free float, up roughly 7% over the past month, with days-to-cover at 12.5 days on FINRA's most recent settlement data. Yet the borrow market offers little ammunition for a squeeze: availability remains comfortable and borrowing costs run at just 0.52% annualised — near their lowest levels of the past six weeks. That points to a position that is large but not stressed. The ORTEX short score of 67.6 is elevated though easing, having retreated from a peak of 70.2 on April 17. Meanwhile the stock has run hard, up 9.6% Monday alone and 14.4% on the week to close at $105.79, leaving it up 22% year-to-date. Options positioning is slightly more defensive than usual — the put/call ratio is running near 1.0, modestly above its 20-day mean of 0.72 — but at a z-score of 0.6, the move is not alarming.
Analysts have been consistently moving targets higher in the run-up, which frames the bull case clearly. HC Wainwright lifted its target to $175 on May 4, the morning of the pre-earnings rally, while Baird raised to $112 and Stifel moved to $130 earlier in the week. The consensus mean price target now sits at $135, implying about 28% upside from Monday's close. Bulls point to Livmarli's broadening applications and the FDA's recent validation of linerixibat — which shares a mechanism with Mirum's volixibat — as a sign the pipeline approach is proven. Bears counter that Livmarli's tolerability profile, specifically a higher discontinuation rate tied to diarrhea relative to linerixibat, is a commercial liability that the company has yet to fully neutralise. Without head-to-head data, the efficacy debate remains open.
The historical earnings record adds a specific edge to the setup. The last two reported quarters both produced sharp negative reactions: the February 2026 print sent the stock down roughly 15% on day one and 19% over the following five days, while the prior event matched almost exactly at -14% intraday and -13% on a five-day basis. That pattern is now running squarely against a stock that just rallied 14% in a week and carries the highest short interest it has seen in a month. Institutional ownership provides a partial buffer — Frazier Life Sciences holds 11.6% and Janus Henderson nearly 10%, with Vanguard and State Street both adding in Q1. But the March cluster of insider sales, when the CEO sold over $3.7 million at around $92, reinforces that management was taking some chips off the table well below the current price.
The Q1 print will test whether the recent commercial momentum in Livmarli revenue is durable enough to shift the narrative away from the tolerance and competition concerns that have driven post-earnings selling in both prior quarters.
See the live data behind this article on ORTEX.
Open MIRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
